AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04260763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition Group
Description: Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
Study NCT04260763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Mobile App
Description: The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking.
Study NCT00502723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical retropubic prostatectomy
Description: Radical retropubic prostatectomy
Study NCT00502723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical laparoscopy prostatectomy
Description: Radical laparoscopy prostatectomy
Study NCT02340013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone acetate
Description: Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
Study NCT02631655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: impact of device 18F-FDOPA PET on treatment decisions
Description: Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
Study NCT03537326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
Study NCT04101357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT411
Description: intravenous
Study NCT04101357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: intravenous
Study NCT04101357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous
Study NCT04101357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: intravenous
Study NCT04333784 — intervention group
Intervention type: OTHER
Intervention: Exercise training
Description: Exercise with blood flow restriction (with a pneumatic cuff).
Study NCT03858855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subject Diary
Description: Complete journal
Study NCT01778933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17
Study NCT04667767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WASH kit
Description: WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
Study NCT04667767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: National standard outpatient treatment for uncomplicated severe acute malnutrition
Study NCT02269020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck Dissection
Description: Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
Study NCT04406961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic transpapillary antegrade sphincterotomy developed by Dr. Dovbenko.
Description: Sph. Oddi consists of a longitudinal and circular smooth muscle layers. Circular muscle fibers form the pancreatic and duodenal parts. Anatomical justification was cutting of only the circular layer of sph Oddi by special sphincterotome. Papillary stenosis and stenosis terminal part of common bile duct due to damage only circular layer sph Oddi. Anterograde direction and hooked form of sphincterotome (endoscopic antegrade sphincterotomy- ASD) allows to capture only need layer and control depth. Also ASD was performed patient with SOD (I-III) with preservation of the longitudinal muscular layer sph Oddi and septum of papilla.
Study NCT04406961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The antegrade sphincterotome developed by Dr. Dovbenko.
Description: A device is represented by a teflon catheter in the distal part of which a double tube of variable shape is created. The proximal part of the ASD sphincterotome consists of a handle, and a metal wire is located inside the teflon catheter for connection to an electrosurgical unit. On the distal part, the teflon catheter is formed of a double tube length is 10 to 35 mm. The metal wire exits the catheter at a distance 10 to 35 mm from the tip and enters into the tip the second teflon tube. The distal part of the knife is formed shape a hook. A metal cutting wire is located between two tubes. Moving the handle the metal wire is shifted. Pushing the metal wire or approaching in the distal part the second tube sets the depth of cut. The incision is made by moving on guidewire in bile duct. The power settings vary.
Study NCT04406961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sphincterotomy.
Description: Endoscopic standard sphincterotomy aims at opening bile duct or pancreatic duct by cutting the papilla and sphincter muscles. After deep bile duct cannulation, the standard sphincterotome is retracted until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary. The extent of the sphincterotomy is limited by the length of the intraduodenal portion of the common bile duct.
Study NCT04406961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The standard sphincterotome.
Description: The standard sphincterotome, the Erlangen pull-type model, consists of a catheter containing a cautery wire exposed 15 to 25 mm near the tip of the instrument. The leading tip distal to the wire, the nose, is 5 to 10 mm in diameter. After deep bile duct cannulation, the sphincterotome is retracted slowly, until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made by lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary.
Study NCT03852641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Length of feeding
Description: Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
Study NCT01988857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
Study NCT04097808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
Study NCT01972503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU and oxaliplatin
Description: Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
Study NCT01972503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)
Description: Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
Study NCT01972503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)
Description: Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
Study NCT04379882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Sedation (Silva)
Description: Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
Study NCT02392741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
Study NCT01057654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg
Study NCT01057654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifibrol
Description: Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
Study NCT00775645 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acetyl-L-carnitine hydrochloride
Description: Given orally
Study NCT00775645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02289079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT02289079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Study NCT01941641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant FOLFOXIRI
Study NCT01941641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT00680043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
Study NCT00680043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
Study NCT00680043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
Study NCT03715166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide Oral Solution
Description: Oral Solution dosed at 0.5mg/mL Taken twice daily
Study NCT03715166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution Taken twice daily
Study NCT01196923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopically Guided Ablation
Description: Visually Guided Ablation using EAS-AC
Study NCT04532957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: QD oral capsules
Study NCT04532957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules
Study NCT03773705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery versus scalpel
Description: Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
Study NCT03181204 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchial biopsy
Description: The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
Study NCT03181204 — intervention group
Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
Study NCT03181204 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
Study NCT05160454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: near infrared spectroscopy
Description: evaluate cerebral blood flow with and without breatholding
Study NCT00696176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT 3 DECOY
Description: single administration to a head and neck tumor
Study NCT02447549 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: One RT plan with whole bladder treated to standard dose.
Study NCT02447549 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SART
Description: Three plans (small, medium \& large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
Study NCT02447549 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DART
Description: Three plans (small, medium \& large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
Study NCT02887521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: pulmonary rehabilitation participant manual
Study NCT02887521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: pulmonary rehabilitation
Study NCT02887521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pedometer
Description: receive a pedometer
Study NCT02887521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: receive a pamphlet with exercises plus the standard course of care
Study NCT02887521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: patients undergo surgery
Study NCT02887521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: patients undergo surgery
Study NCT03128333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RunKeeper app + physiotherapy coaching
Description: RunKeeper app for half a year to self-monitor leisure-time PA.
Study NCT03128333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
Study NCT04177342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
Study NCT04177342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
Study NCT02966587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02966587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03668314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDN-929
Description: Single dose from 2 mg to TBD
Study NCT03668314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo Single dose
Study NCT03668314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDN-929 TBD dose
Description: Fed vs fast dose TBD based upon results of previous cohorts
Study NCT03668314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDN-929
Description: Multiple dose based on results of previous cohorts
Study NCT03668314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo multiple dose
Study NCT04620720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capule gabapentin
Description: neuropathic analgesic
Study NCT01569711 — intervention group
Intervention type: PROCEDURE
Intervention: Deep brain stimulation of nucleus accumbens
Description: * Day0 : surgical placement of electrodes~* M1 : stimulation of nucleus accumbens~* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)
Study NCT02530554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Single application
Study NCT02530554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG
Description: Single application
Study NCT02355353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: imaging arm
Description: DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
Study NCT03487757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises
Description: Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.
Study NCT03487757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
Study NCT00005972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00692393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann intervention
Description: sigmoid resection, peritoneal and rectal lavage, terminal stoma
Study NCT00692393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protected anastomosis resection
Description: sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
Study NCT00005972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT02138760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI UroNav fusion biopsy
Study NCT01752907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Education DVD
Description: A general chemotherapy side effects education DVD
Study NCT01752907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Pain Education DVD
Study NCT02543645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Varlilumab and Atezolizumab
Description: Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg.
Study NCT00816231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco
Description: Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.